Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Ensysce Biosciences, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −1 vs. Q2 2022
- Shares held
- 3.78M
- −140.3K (−3.6%) vs. Q2 2022
- Total value
- $832.7K
- −$2.57M (−75.5%) vs. Q2 2022
- New holders
- 5
- 7 more added
- Sold out
- 6
- 1 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENSC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 18 | $261.1K |
| Q1 2026 | 15 | $261.5K |
| Q4 2025 | 17 | $461.1K |
| Q3 2025 | 17 | $833.7K |
| Q2 2025 | 11 | $398.8K |
| Q1 2025 | 9 | $903.4K |
| Q4 2024 | 8 | $1.15M |
| Q3 2024 | 13 | $580.5K |
| Q2 2024 | 11 | $253.0K |
| Q1 2024 | 10 | $236.5K |
| Q4 2023 | 9 | $56.4K |
| Q3 2023 | 12 | $231.1K |
| Q2 2023 | 9 | $714.0K |
| Q1 2023 | 10 | $103.2K |
| Q4 2022 | 14 | $138.2K |
| Q3 2022 | 20 | $832.7K |
| Q2 2022 | 21 | $3.41M |
| Q1 2022 | 21 | $6.23M |
| Q4 2021 | 18 | $15.9M |
| Q3 2021 | 16 | $9.56M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Ensysce Biosciences, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| HG Vora Capital Management, LLC | 2,462,500 | $529.0K | 0.02% | 00.0% | Unchanged |
| Vanguard Group Inc | 315,828 | $68.0K | 0.00% | +193,475+158.1% | Added |
| BlackRock Inc. | 234,240 | $50.0K | 0.00% | 00.0% | Unchanged |
| Stifel Financial Corp | 216,642 | $47.0K | 0.00% | 00.0% | Unchanged |
| Cerity Partners LLC | 150,000 | $32.0K | 0.00% | +150,000 | New |
| Geode Capital Management, LLC | 130,523 | $28.0K | 0.00% | +3,175+2.5% | Added |
| Moneta Group Investment Advisors LLC | 5,116 | $22.0K | 0.00% | +5,116 | New |
| UBS Group AG | 52,142 | $11.0K | 0.00% | +35,055+205.2% | Added |
| Northern Trust Corp | 51,089 | $11.0K | 0.00% | +51,089 | New |
| Virtu Financial LLC | 41,789 | $9.00K | 0.00% | +41,789 | New |
| State Street Corp | 35,551 | $8.00K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 33,994 | $7.00K | 0.00% | +9,960+41.4% | Added |
| Jane Street Group, LLC | 20,431 | $4.00K | 0.00% | +20,431 | New |
| Tower Research Capital LLC (TRC) | 15,433 | $3.00K | 0.00% | +12,369+403.7% | Added |
| StoneX Group Inc. | 12,781 | $2.75K | 0.00% | +911+7.7% | Added |
| Wolverine Asset Management LLC | 4,987 | $1.00K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 151 | $0 | 0.00% | +12+8.6% | Added |
| Morgan Stanley | 3 | $0 | 0.00% | −267−98.9% | Reduced |
| Covington Capital Management | 100 | $0 | 0.00% | 00.0% | Unchanged |
| FNY Investment Advisers, LLC | 20 | $0 | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −356,325−100.0% | Sold out |
| Anson Funds Management LP | 0 | $0 | 0.00% | −150,664−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −70,940−100.0% | Sold out |
| Powell Investment Advisors, LLC | 0 | $0 | 0.00% | −70,000−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −15,393−100.0% | Sold out |
| Cutler Group LP | 0 | $0 | 0.00% | −100−100.0% | Sold out |